Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 736

1.

Gargle lavage as a safe and sensitive alternative to swab samples to diagnose COVID-19: a case report in Japan.

Saito M, Adachi E, Yamayoshi S, Koga M, Iwatsuki-Horimoto K, Kawaoka Y, Yotsuyanagi H.

Clin Infect Dis. 2020 Apr 2. pii: ciaa377. doi: 10.1093/cid/ciaa377. [Epub ahead of print] No abstract available.

PMID:
32241023
2.

Optimization of animal models to better predict influenza vaccine efficacy (VA).

Neumann G, Kawaoka Y.

Vaccine. 2020 Mar 17;38(13):2749-2750. doi: 10.1016/j.vaccine.2020.01.102. No abstract available.

PMID:
32145878
3.

Pandemic potential of highly pathogenic avian influenza clade 2.3.4.4 A(H5) viruses.

Yamaji R, Saad MD, Davis CT, Swayne DE, Wang D, Wong FYK, McCauley JW, Peiris JSM, Webby RJ, Fouchier RAM, Kawaoka Y, Zhang W.

Rev Med Virol. 2020 Mar 5:e2099. doi: 10.1002/rmv.2099. [Epub ahead of print] Review.

PMID:
32135031
4.

High Levels of miR-483-3p Are Present in Serum Exosomes Upon Infection of Mice With Highly Pathogenic Avian Influenza Virus.

Maemura T, Fukuyama S, Kawaoka Y.

Front Microbiol. 2020 Feb 11;11:144. doi: 10.3389/fmicb.2020.00144. eCollection 2020.

5.

Villains or heroes? The raison d'être of viruses.

Watanabe T, Kawaoka Y.

Clin Transl Immunology. 2020 Feb 19;9(2):e01114. doi: 10.1002/cti2.1114. eCollection 2020. Review.

6.

Uncovering the Anti-Ebola Repertome.

Yamayoshi S, Kawaoka Y.

Cell Host Microbe. 2020 Feb 12;27(2):163-165. doi: 10.1016/j.chom.2020.01.014.

PMID:
32053784
7.

Comparison of the Pathogenicity in Mice of A(H1N1)pdm09 Viruses Isolated between 2009 and 2015 in Japan.

Mitake H, Yasuhara A, Lopes TJS, Tagawa-Sakai Y, Shimizu K, Ozawa H, Kawakami C, Morikawa S, Sugaya N, Watanabe T, Kawaoka Y.

Viruses. 2020 Jan 29;12(2). pii: E155. doi: 10.3390/v12020155.

8.

Multicolor two-photon imaging of in vivo cellular pathophysiology upon influenza virus infection using the two-photon IMPRESS.

Ueki H, Wang IH, Zhao D, Gunzer M, Kawaoka Y.

Nat Protoc. 2020 Mar;15(3):1041-1065. doi: 10.1038/s41596-019-0275-y. Epub 2020 Jan 29.

9.

Antigenic variants of influenza B viruses isolated in Japan during the 2017-2018 and 2018-2019 influenza seasons.

Kato-Miyashita S, Sakai-Tagawa Y, Yamashita M, Iwatsuki-Horimoto K, Ito M, Tokita A, Hagiwara H, Izumida N, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Yotsuyanagi H, Kawaoka Y, Imai M.

Influenza Other Respir Viruses. 2020 Jan 19. doi: 10.1111/irv.12713. [Epub ahead of print]

10.

A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades.

Furuyama W, Reynolds P, Haddock E, Meade-White K, Quynh Le M, Kawaoka Y, Feldmann H, Marzi A.

NPJ Vaccines. 2020 Jan 10;5:4. doi: 10.1038/s41541-019-0155-z. eCollection 2020.

11.

Correction: Genetics, Receptor Binding Property, and Transmissibility in Mammals of Naturally Isolated H9N2 Avian Influenza Viruses.

Li X, Shi J, Guo J, Deng G, Zhang Q, Wang J, He X, Wang K, Chen J, Li Y, Fan J, Kong H, Gu C, Guan Y, Suzuki Y, Kawaoka Y, Liu L, Jiang Y, Tian G, Li Y, Bu Z, Chen H.

PLoS Pathog. 2020 Jan 8;16(1):e1008284. doi: 10.1371/journal.ppat.1008284. eCollection 2020 Jan.

12.

G Protein Pathway Suppressor 1 Promotes Influenza Virus Polymerase Activity by Activating the NF-κB Signaling Pathway.

Kuwahara T, Yamayoshi S, Noda T, Kawaoka Y.

mBio. 2019 Dec 17;10(6). pii: e02867-19. doi: 10.1128/mBio.02867-19.

13.

Baloxavir marboxil treatment of nude mice infected with influenza A virus.

Kiso M, Yamayoshi S, Murakami J, Kawaoka Y.

J Infect Dis. 2019 Dec 14. pii: jiz665. doi: 10.1093/infdis/jiz665. [Epub ahead of print]

PMID:
31837268
14.

Mutations in the Neuraminidase-Like Protein of Bat Influenza H18N11 Virus Enhance Virus Replication in Mammalian Cells, Mice, and Ferrets.

Zhong G, Fan S, Hatta M, Nakatsu S, Walters KB, Lopes TJS, Wang JI, Ozawa M, Karasin A, Li Y, Tong S, Donis RO, Neumann G, Kawaoka Y.

J Virol. 2020 Feb 14;94(5). pii: e01416-19. doi: 10.1128/JVI.01416-19. Print 2020 Feb 14.

PMID:
31801857
15.

Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets.

Imai M, Yamashita M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kiso M, Murakami J, Yasuhara A, Takada K, Ito M, Nakajima N, Takahashi K, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bakel H, Tokita A, Hagiwara H, Izumida N, Kuroki H, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Hasegawa H, Kawaoka Y.

Nat Microbiol. 2020 Jan;5(1):27-33. doi: 10.1038/s41564-019-0609-0. Epub 2019 Nov 25.

PMID:
31768027
16.

Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil.

Kiso M, Yamayoshi S, Furusawa Y, Imai M, Kawaoka Y.

Viruses. 2019 Nov 15;11(11). pii: E1066. doi: 10.3390/v11111066.

17.

Sensitivity of Commercially Available Influenza Rapid Diagnostic Tests in the 2018-2019 Influenza Season.

Sakai-Tagawa Y, Yamayoshi S, Kawaoka Y.

Front Microbiol. 2019 Oct 11;10:2342. doi: 10.3389/fmicb.2019.02342. eCollection 2019.

18.

Antigenic Change in Human Influenza A(H2N2) Viruses Detected by Using Human Plasma from Aged and Younger Adult Individuals.

Matsuzawa Y, Iwatsuki-Horimoto K, Nishimoto Y, Abe Y, Fukuyama S, Hamabata T, Okuda M, Go Y, Watanabe T, Imai M, Arai Y, Fouchier RAM, Yamayoshi S, Kawaoka Y.

Viruses. 2019 Oct 23;11(11). pii: E978. doi: 10.3390/v11110978.

19.

Characterization of H7N9 avian influenza viruses isolated from duck meat products.

Wu L, Mitake H, Kiso M, Ito M, Iwatsuki-Hirimoto K, Yamayoshi S, Lopes TJS, Feng H, Sumiyoshi R, Shibata A, Osaka H, Imai M, Watanabe T, Kawaoka Y.

Transbound Emerg Dis. 2020 Mar;67(2):792-798. doi: 10.1111/tbed.13398. Epub 2019 Nov 6.

PMID:
31650680
20.

Oseltamivir Is Effective against 1918 Influenza Virus Infection of Macaques but Vulnerable to Escape.

Feldmann F, Kobasa D, Embury-Hyatt C, Grolla A, Taylor T, Kiso M, Kakugawa S, Gren J, Jones SM, Kawaoka Y, Feldmann H.

mBio. 2019 Oct 22;10(5). pii: e02059-19. doi: 10.1128/mBio.02059-19.

21.

A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice.

Feng H, Nakajima N, Wu L, Yamashita M, Lopes TJS, Tsuji M, Hasegawa H, Watanabe T, Kawaoka Y.

Front Microbiol. 2019 Sep 18;10:2157. doi: 10.3389/fmicb.2019.02157. eCollection 2019.

22.

The Role of EGFR in Influenza Pathogenicity: Multiple Network-Based Approaches to Identify a Key Regulator of Non-lethal Infections.

Mitchell HD, Eisfeld AJ, Stratton KG, Heller NC, Bramer LM, Wen J, McDermott JE, Gralinski LE, Sims AC, Le MQ, Baric RS, Kawaoka Y, Waters KM.

Front Cell Dev Biol. 2019 Sep 20;7:200. doi: 10.3389/fcell.2019.00200. eCollection 2019.

23.

Influenza Virus Polymerase Mutation Stabilizes a Foreign Gene Inserted into the Virus Genome by Enhancing the Transcription/Replication Efficiency of the Modified Segment.

Furusawa Y, Yamada S, da Silva Lopes TJ, Dutta J, Khan Z, Kriti D, van Bakel H, Kawaoka Y.

mBio. 2019 Oct 1;10(5). pii: e01794-19. doi: 10.1128/mBio.01794-19.

24.

Food Additives as Novel Influenza Vaccine Adjuvants.

Feng H, Yamashita M, Wu L, Jose da Silva Lopes T, Watanabe T, Kawaoka Y.

Vaccines (Basel). 2019 Sep 24;7(4). pii: E127. doi: 10.3390/vaccines7040127.

25.

Soluble Recombinant Hemagglutinin Protein of H1N1pdm09 Influenza Virus Elicits Cross-Protection Against a Lethal H5N1 Challenge in Mice.

Yamada S, Yasuhara A, Kawaoka Y.

Front Microbiol. 2019 Sep 4;10:2031. doi: 10.3389/fmicb.2019.02031. eCollection 2019.

26.

Identification of a distinct lineage of aviadenovirus from crane feces.

Mukai Y, Tomita Y, Kryukov K, Nakagawa S, Ozawa M, Matsui T, Tomonaga K, Imanishi T, Kawaoka Y, Watanabe T, Horie M.

Virus Genes. 2019 Dec;55(6):815-824. doi: 10.1007/s11262-019-01703-w. Epub 2019 Sep 23.

PMID:
31549291
27.

Neo-virology: The raison d'etre of viruses.

Watanabe T, Suzuki N, Tomonaga K, Sawa H, Matsuura Y, Kawaguchi Y, Takahashi H, Nagasaki K, Kawaoka Y.

Virus Res. 2019 Dec;274:197751. doi: 10.1016/j.virusres.2019.197751. Epub 2019 Sep 11.

PMID:
31520652
28.

Long-term culture of human lung adenocarcinoma A549 cells enhances the replication of human influenza A viruses.

Ujie M, Takada K, Kiso M, Sakai-Tagawa Y, Ito M, Nakamura K, Watanabe S, Imai M, Kawaoka Y.

J Gen Virol. 2019 Oct;100(10):1345-1349. doi: 10.1099/jgv.0.001314.

PMID:
31424377
29.

Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys.

Arikata M, Itoh Y, Shichinohe S, Nakayama M, Ishigaki H, Kinoshita T, Le MQ, Kawaoka Y, Ogasawara K, Shimizu T.

Antiviral Res. 2019 Nov;171:104591. doi: 10.1016/j.antiviral.2019.104591. Epub 2019 Aug 14.

PMID:
31421167
30.

A Novel Vaccine Strategy to Overcome Poor Immunogenicity of Avian Influenza Vaccines through Mobilization of Memory CD4 T Cells Established by Seasonal Influenza.

DiPiazza AT, Fan S, Rattan A, DeDiego ML, Chaves F, Neumann G, Kawaoka Y, Sant AJ.

J Immunol. 2019 Sep 15;203(6):1502-1508. doi: 10.4049/jimmunol.1900819. Epub 2019 Aug 9.

PMID:
31399519
31.

Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study.

Halfmann PJ, Eisfeld AJ, Watanabe T, Maemura T, Yamashita M, Fukuyama S, Armbrust T, Rozich I, N'jai A, Neumann G, Kawaoka Y, Sahr F.

PLoS Negl Trop Dis. 2019 Aug 1;13(8):e0007654. doi: 10.1371/journal.pntd.0007654. eCollection 2019 Aug.

32.

Effective mosaic-based nanovaccines against avian influenza in poultry.

Kingstad-Bakke BA, Chandrasekar SS, Phanse Y, Ross KA, Hatta M, Suresh M, Kawaoka Y, Osorio JE, Narasimhan B, Talaat AM.

Vaccine. 2019 Aug 14;37(35):5051-5058. doi: 10.1016/j.vaccine.2019.06.077. Epub 2019 Jul 9.

PMID:
31300285
33.

Isolation of Highly Pathogenic H5N1 Influenza Viruses in 2009-2013 in Vietnam.

Zhong G, Fan S, Lopes TJS, Le MQ, van Bakel H, Dutta J, Smith GJD, Jayakumar J, Nguyen HLK, Hoang PVM, Halfmann P, Hatta M, Su YCF, Neumann G, Kawaoka Y.

Front Microbiol. 2019 Jun 25;10:1411. doi: 10.3389/fmicb.2019.01411. eCollection 2019.

34.

Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.

Moser MJ, Hatta Y, Gabaglia C, Sanchez A, Dias P, Sarawar S, Kawaoka Y, Hatta M, Neumann G, Bilsel P.

Vaccine. 2019 Jul 26;37(32):4533-4542. doi: 10.1016/j.vaccine.2019.06.043. Epub 2019 Jul 4.

35.

A single amino acid change in hemagglutinin reduces the cross-reactivity of antiserum against an equine influenza vaccine strain.

Nemoto M, Yamayoshi S, Bannai H, Tsujimura K, Kokado H, Kawaoka Y, Yamanaka T.

Arch Virol. 2019 Sep;164(9):2355-2358. doi: 10.1007/s00705-019-04328-4. Epub 2019 Jun 21.

PMID:
31227892
36.

Low Polymerase Activity Attributed to PA Drives the Acquisition of the PB2 E627K Mutation of H7N9 Avian Influenza Virus in Mammals.

Liang L, Jiang L, Li J, Zhao Q, Wang J, He X, Huang S, Wang Q, Zhao Y, Wang G, Sun N, Deng G, Shi J, Tian G, Zeng X, Jiang Y, Liu L, Liu J, Chen P, Bu Z, Kawaoka Y, Chen H, Li C.

mBio. 2019 Jun 18;10(3). pii: e01162-19. doi: 10.1128/mBio.01162-19.

37.

Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection.

Davis CW, Jackson KJL, McElroy AK, Halfmann P, Huang J, Chennareddy C, Piper AE, Leung Y, Albariño CG, Crozier I, Ellebedy AH, Sidney J, Sette A, Yu T, Nielsen SCA, Goff AJ, Spiropoulou CF, Saphire EO, Cavet G, Kawaoka Y, Mehta AK, Glass PJ, Boyd SD, Ahmed R.

Cell. 2019 May 30;177(6):1566-1582.e17. doi: 10.1016/j.cell.2019.04.036. Epub 2019 May 16.

38.

A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses.

Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, Shimizu K, Takasaki S, Sakai-Tagawa Y, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bakel H, Yamada S, Watanabe T, Imai M, Kawaoka Y.

Nat Microbiol. 2019 Aug;4(8):1268-1273. doi: 10.1038/s41564-019-0433-6. Epub 2019 Apr 29.

PMID:
31036910
39.

Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018.

Okuda M, Yamayoshi S, Uraki R, Ito M, Hamabata T, Kawaoka Y.

Viruses. 2019 Apr 2;11(4). pii: E321. doi: 10.3390/v11040321.

40.

Identification of Amino Acid Residues in Influenza A Virus PA-X That Contribute to Enhanced Shutoff Activity.

Oishi K, Yamayoshi S, Kawaoka Y.

Front Microbiol. 2019 Mar 6;10:432. doi: 10.3389/fmicb.2019.00432. eCollection 2019.

41.

Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus.

Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Koga M, Adachi E, Kikuchi T, Wang IH, Yamada S, Kawaoka Y.

Nat Microbiol. 2019 Jun;4(6):1024-1034. doi: 10.1038/s41564-019-0401-1. Epub 2019 Mar 18.

PMID:
30886361
42.

Clinical significance of periosteal reaction as a predictive factor for treatment outcome of medication-related osteonecrosis of the jaw.

Kojima Y, Kawaoka Y, Sawada S, Hayashida S, Okuyama K, Yutori H, Kawakita A, Ishida S, Soutome S, Yanamoto S, Umeda M, Iwai H.

J Bone Miner Metab. 2019 Sep;37(5):913-919. doi: 10.1007/s00774-019-00994-1. Epub 2019 Mar 4.

PMID:
30830278
43.

Plasma lipidome reveals critical illness and recovery from human Ebola virus disease.

Kyle JE, Burnum-Johnson KE, Wendler JP, Eisfeld AJ, Halfmann PJ, Watanabe T, Sahr F, Smith RD, Kawaoka Y, Waters KM, Metz TO.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3919-3928. doi: 10.1073/pnas.1815356116. Epub 2019 Feb 11.

44.

Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons.

Kawakami C, Yamayoshi S, Akimoto M, Nakamura K, Miura H, Fujisaki S, Pattinson DJ, Shimizu K, Ozawa H, Momoki T, Saikusa M, Yasuhara A, Usuku S, Okubo I, Toyozawa T, Sugita S, Smith DJ, Watanabe S, Kawaoka Y.

Euro Surveill. 2019 Feb;24(6). doi: 10.2807/1560-7917.ES.2019.24.6.1800467.

45.

Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus.

Ito M, Yamayoshi S, Murakami K, Saito K, Motojima A, Nakaishi K, Kawaoka Y.

Viruses. 2019 Feb 11;11(2). pii: E149. doi: 10.3390/v11020149.

46.

Host protein mimics viral protein to hinder infection by Ebola virus.

Yamayoshi S, Kawaoka Y.

Nature. 2019 Feb;566(7743):190-191. doi: 10.1038/d41586-019-00182-1. No abstract available.

PMID:
30737499
47.

Injectable Excipients as Novel Influenza Vaccine Adjuvants.

Feng H, Yamashita M, da Silva Lopes TJ, Watanabe T, Kawaoka Y.

Front Microbiol. 2019 Jan 24;10:19. doi: 10.3389/fmicb.2019.00019. eCollection 2019.

48.

Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.

Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE Jr.

J Virol. 2019 Apr 3;93(8). pii: e01439-18. doi: 10.1128/JVI.01439-18. Print 2019 Apr 15.

49.

Predicting the Next Influenza Pandemics.

Neumann G, Kawaoka Y.

J Infect Dis. 2019 Apr 8;219(Supplement_1):S14-S20. doi: 10.1093/infdis/jiz040.

PMID:
30715371
50.

C57BL/6J and C57BL/6NJ Mice Are Differentially Susceptible to Inflammation-Associated Disease Caused by Influenza A Virus.

Eisfeld AJ, Gasper DJ, Suresh M, Kawaoka Y.

Front Microbiol. 2019 Jan 17;9:3307. doi: 10.3389/fmicb.2018.03307. eCollection 2018.

Supplemental Content

Loading ...
Support Center